Loading
The selective TRK inhibitor larotrectinib shrank tumours in three quarters of patients with NTRK fusions across 17 different cancer types and ages from infancy to old age, leading to the first tumour-agnostic approval of a targeted drug.
Pooled analysis of 55 patients (adults and children) with TRK fusion-positive solid tumours across 17 tumour types from three phase 1 and 2 trials treated with larotrectinib.
Objective response was 75 percent by independent review with 71 percent of responses ongoing at one year, activity independent of tumour type, fusion partner or age, and mostly low-grade toxicity.
NTRK fusion testing is now recommended in lung and other cancers without a common driver, and larotrectinib or entrectinib is the standard treatment when a fusion is found.